Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
Stifel Maintains Verve Therapeutics(VERV.US) With Buy Rating
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Verve Therapeutics Has Positive Read From NewAmsterdam Data, Says Stifel
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
Express News | Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Bvf Partners LP Reports 8.2% Passive Stake in Verve Therapeutics Inc as of Nov 11 - SEC Filing
ARKK's Holdings Ranked by SA Quant Grades
CRISPR, Beam, Other Gene Editing Names up Significantly
RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17
J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23
CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32
RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating
Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Verve Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Verve Therapeutics(VERV.US), With a Forecast Between $14 to $23
Positive Outlook on Verve Therapeutics: Promising VERVE-102 Trial Results and Genetic Editing Advancements
Verve Therapeutics Price Target Lowered to $14 From $15 at H.C. Wainwright